CD8A and neoplasm: Researchers used a genome-scale CRISPR/Cas9 library containing around 123,000 single-guide RNAs to profile genes whose loss in tumour cells damaged the effector function of CD8+ T cells and contributed to the T-cell-based immunotherapy resistance (14).